Anika Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	112.82	119.91	120.79	113.83	147.79
Revenue Growth (YoY)	-5.91%	-0.73%	6.12%	-22.98%	13.29%
Cost of Revenue	49.01	43.3	37.51	40.61	58.39
Gross Profit	63.81	76.6	83.28	73.22	89.41
Selling, General & Admin	49.09	55.56	59.93	51.23	74.1
Research & Development	25.77	25.54	21.76	18.32	27.33
Operating Expenses	74.86	81.1	81.69	69.55	101.42
Operating Income	-11.05	-4.5	1.59	3.67	-12.02
Interest Expense	-	-	-	-	-0.19
Interest & Investment Income	1.74	2.34	2.31	0.65	-
EBT Excluding Unusual Items	-9.31	-2.16	3.9	4.32	-12.2
Merger & Restructuring Charges	-	-0.61	-0.75	-	-6.47
Other Unusual Items	-	-	-	-	21.1
Pretax Income	-9.31	-2.76	3.16	4.32	2.43
Income Tax Expense	0.67	6.06	6.6	2.12	-1.71
Earnings From Continuing Operations	-9.98	-8.83	-3.44	2.2	4.13
Earnings From Discontinued Operations	-0.9	-47.56	-79.23	-17.06	-
Net Income	-10.88	-56.39	-82.67	-14.86	4.13
Net Income to Common	-10.88	-56.39	-82.67	-14.86	4.13
Shares Outstanding (Basic)	14	15	15	15	14
Shares Outstanding (Diluted)	14	15	15	15	15
Shares Change (YoY)	-2.60%	0.44%	0.65%	-0.50%	2.90%
EPS (Basic)	-0.76	-3.83	-5.64	-1.02	0.29
EPS (Diluted)	-0.76	-3.83	-5.64	-1.02	0.28
Free Cash Flow	4.36	-2.33	-7.22	-3.08	3.25
Free Cash Flow Per Share	0.30	-0.16	-0.49	-0.21	0.22
Gross Margin	56.56%	63.89%	68.95%	64.33%	60.49%
Operating Margin	-9.79%	-3.75%	1.32%	3.22%	-8.13%
Profit Margin	-9.64%	-47.02%	-68.44%	-13.05%	2.80%
Free Cash Flow Margin	3.87%	-1.94%	-5.97%	-2.70%	2.20%
EBITDA	-5.32	3.63	15.81	18.16	2.3
EBITDA Margin	-4.72%	3.02%	13.09%	15.95%	1.56%
D&A For EBITDA	5.73	8.12	14.22	14.49	14.32
EBIT	-11.05	-4.5	1.59	3.67	-12.02
EBIT Margin	-9.79%	-3.75%	1.32%	3.22%	-8.13%
Effective Tax Rate	-	-	208.97%	49.12%	-

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q